ArticleJournal of hematopathology2025
Immunohistochemical evaluation of T cell receptor and T cell receptor beta constant 1 expression distinguishes benign and neoplastic immature T-cell populations and reveals discrete TRBC1/TCR phenotypes.
Article in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Special Issue "Flow Cytometry: Applications and Challenges".International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExpression of TRBC1 and TRBC2 is increasingly assessed in the evaluation for clonal T-cell populations. While flow cytometry has repeatedly shown utility in evaluating TRBC 1/2 expression, immunohistochemical (IHC) methods have not been extensively examined, particularly in immature T-cell populations. PURPOSE: This study evaluated TRBC1 IHC staining in formalin-fixed paraffin-embedded (FFPE) tissue, encompassing benign thymic tissue, thymomas, and T-lymphoblastic leukemias/lymphomas (T-LL).
methodsIHC for TRBC1, CD3, TCR-BF1, and TCR-δ was performed in all cases; TdT was performed on all T-LLs. TRBC1 was scored as positively restricted (≥ 85%), negatively restricted (≤ 15%), or polytypic (16-84%) in T cells, using CD3 and/or TdT staining as the denominator.
resultsAll thymic tissues (n = 6) and thymomas (n = 5) showed polytypic TRBC1 staining patterns. Twenty-four T-LL specimens were identified from 21 patients, including bone marrow (n = 16), lymph node (n = 7), and bone (n = 1) biopsies. All T-LL cases showed positively (n = 3 patients, 14%) or negatively (n = 18 patients, 86%) restricted TRBC1 expression. Patients with multiple specimens showed consistent TRBC1 staining across tissue sites and sampling time points. Coexpression analysis of TRBC1, TCR-BF1, and TCR-δ staining revealed frequent TRBC1-negative cases with either TCR-δ + (n = 6, 29%) or TCR null (n = 7, 33%) phenotypes. TRBC1 IHC restriction and molecular methods for clonality assessment were concordant in 13 of 15 evaluated cases (87%).
conclusionsT-LL showed restricted patterns of TRBC1 expression by IHC, whereas benign immature T-cell populations showed polytypic staining. The observed TCR and TRBC1 phenotypes of T-LL are distinct from those of mature T-cell neoplasms and warrant further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.